Pretomanid - Global Alliance for TB Drug Development

Drug Profile

Pretomanid - Global Alliance for TB Drug Development

Alternative Names: PA 824

Latest Information Update: 01 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Global Alliance for TB Drug Development
  • Class 2 ring heterocyclic compounds; Antituberculars; Nitroimidazoles; Oxazines; Phenyl ethers; Small molecules
  • Mechanism of Action Cell wall inhibitors; Nitric oxide stimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Tuberculosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 May 2018 Global Alliance for TB Drug Development completes a phase III trial for Tuberculosis (Combination therapy) in Africa (including Mozambique, Zambia, Uganda, Kenya, South Africa and Tanzania), Asia (including Thailand, Philippines, Malaysia, China), Ukraine, Russia, Peru, Haiti, Georgia and Brazil (PO) (NCT02342886)
  • 21 Nov 2017 Phase-III clinical trials in Tuberculosis (Combination therapy, In adolescents, In the elderly, Treatment-experienced, In adults) in Georgia (PO) (NCT03086486)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top